Highlights
- Rather than conducting the trial at many different facilities, all patients come to one facility
- No need to additionally train clinicians at other centres
- All tests performed under one roof, ensuring high consistency and quality
- Thanks to shorter timelines and better consistency, we can offer superior results at lower cost
More patients in early-phase drug development
In recent years, we have seen an increased demand for more information and insight from early-stage studies. Sponsors want to know more than just whether their product is tolerated by patients: they want to actually see what it does in patients already in the early phases of development. Having anticipated this demand, CHDR is uniquely positioned to perform single-centre, early-stage studies in patients. We offer a diverse array of high-tech measurements, including our NeuroCart® battery and complex biomarkers, which would be nearly impossible to perform in a multicentre setup. By bringing all participating patients to our facility, we can collect a wide variety of complex data. The Monocentre approach thus facilitates the information-rich approach to early-phase drug development, supporting sponsors in making key strategic decisions.
